MEDICATIONS: As the FDA cuts back on approvals, experts predict greater focus on treating rarer diseases. WASHINGTON - There is no quick remedy for what ails the pharmaceutical industry: a tougher environment for drug approvals and a dwindling pipeline of new medications.

Originally Syndicated via RSS from Yahoo! News Search Results for vioxx